Free Trial

Alumis (ALMS) Competitors

Alumis logo
$4.51 -0.10 (-2.17%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$4.46 -0.04 (-1.00%)
As of 10/24/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALMS vs. STOK, VCEL, RCUS, TLRY, TWST, BHVN, IMCR, ABCL, PAHC, and JANX

Should you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Stoke Therapeutics (STOK), Vericel (VCEL), Arcus Biosciences (RCUS), Tilray Brands (TLRY), Twist Bioscience (TWST), Biohaven (BHVN), Immunocore (IMCR), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.

Alumis vs. Its Competitors

Alumis (NASDAQ:ALMS) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Alumis has a beta of -1.47, suggesting that its stock price is 247% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.

Stoke Therapeutics has a net margin of 26.25% compared to Alumis' net margin of 0.00%. Stoke Therapeutics' return on equity of 18.32% beat Alumis' return on equity.

Company Net Margins Return on Equity Return on Assets
AlumisN/A -119.15% -92.50%
Stoke Therapeutics 26.25%18.32%15.48%

Stoke Therapeutics has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alumis$20.06M23.40-$294.23M-$4.72-0.96
Stoke Therapeutics$199.89M8.85-$88.98M$0.8537.98

Alumis currently has a consensus target price of $20.17, suggesting a potential upside of 347.15%. Stoke Therapeutics has a consensus target price of $30.83, suggesting a potential downside of 4.48%. Given Alumis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Alumis is more favorable than Stoke Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alumis
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

In the previous week, Stoke Therapeutics had 5 more articles in the media than Alumis. MarketBeat recorded 9 mentions for Stoke Therapeutics and 4 mentions for Alumis. Alumis' average media sentiment score of 1.10 beat Stoke Therapeutics' score of 0.89 indicating that Alumis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alumis
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Stoke Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Stoke Therapeutics beats Alumis on 9 of the 14 factors compared between the two stocks.

Get Alumis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALMS vs. The Competition

MetricAlumisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$469.33M$3.42B$6.24B$10.69B
Dividend YieldN/A2.27%5.72%4.81%
P/E Ratio-0.9628.2931.4730.88
Price / Sales23.40467.43564.64176.26
Price / CashN/A46.1437.0861.44
Price / Book0.8210.4012.056.61
Net Income-$294.23M-$52.83M$3.33B$277.10M
7 Day Performance0.45%2.10%1.93%2.56%
1 Month Performance13.03%12.33%7.77%3.77%
1 Year Performance-62.10%14.14%56.40%33.01%

Alumis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALMS
Alumis
3.2689 of 5 stars
$4.51
-2.2%
$20.17
+347.2%
-62.3%$469.33M$20.06M-0.96N/ANews Coverage
Positive News
Analyst Forecast
STOK
Stoke Therapeutics
3.2784 of 5 stars
$33.53
-1.9%
$30.83
-8.0%
+167.9%$1.84B$36.56M39.45100Analyst Forecast
Gap Up
VCEL
Vericel
3.4507 of 5 stars
$35.32
+1.6%
$58.40
+65.3%
-15.3%$1.78B$237.22M294.36300Analyst Forecast
RCUS
Arcus Biosciences
2.7657 of 5 stars
$16.49
-0.7%
$26.78
+62.4%
-2.9%$1.76B$258M-5.20500Analyst Forecast
TLRY
Tilray Brands
3.2321 of 5 stars
$1.56
+1.3%
$2.00
+28.2%
-9.1%$1.72B$821.31M-0.692,842Analyst Forecast
TWST
Twist Bioscience
4.0023 of 5 stars
$28.16
-8.4%
$48.56
+72.4%
-15.2%$1.70B$312.97M-19.42990Analyst Forecast
Gap Up
BHVN
Biohaven
3.4108 of 5 stars
$16.00
-2.9%
$48.85
+205.3%
-68.3%$1.69BN/A-2.09239News Coverage
Analyst Forecast
IMCR
Immunocore
2.6796 of 5 stars
$33.56
+0.1%
$56.89
+69.5%
+1.8%$1.69B$310.20M-83.90320News Coverage
Analyst Forecast
ABCL
AbCellera Biologics
2.4212 of 5 stars
$5.59
-4.3%
$8.00
+43.1%
+109.6%$1.67B$28.83M-10.16500Analyst Forecast
Gap Up
PAHC
Phibro Animal Health
3.8265 of 5 stars
$39.72
+3.0%
$28.40
-28.5%
+80.8%$1.61B$1.30B33.662,475News Coverage
Insider Trade
JANX
Janux Therapeutics
1.9722 of 5 stars
$26.76
-1.6%
$78.31
+192.6%
-53.3%$1.61B$10.59M-14.8730News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ALMS) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners